WO1999042477A3 - Transporterprotein für saccharid-gekoppelte arzneimittel - Google Patents

Transporterprotein für saccharid-gekoppelte arzneimittel Download PDF

Info

Publication number
WO1999042477A3
WO1999042477A3 PCT/DE1999/000535 DE9900535W WO9942477A3 WO 1999042477 A3 WO1999042477 A3 WO 1999042477A3 DE 9900535 W DE9900535 W DE 9900535W WO 9942477 A3 WO9942477 A3 WO 9942477A3
Authority
WO
WIPO (PCT)
Prior art keywords
transporter
nucleic acid
saccharide
medicaments
coupled
Prior art date
Application number
PCT/DE1999/000535
Other languages
English (en)
French (fr)
Other versions
WO1999042477A2 (de
WO1999042477A8 (de
Inventor
Hermann Koepsell
Manfred Wiessler
Original Assignee
Deutsches Krebsforsch
Hermann Koepsell
Manfred Wiessler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Hermann Koepsell, Manfred Wiessler filed Critical Deutsches Krebsforsch
Priority to JP2000532429A priority Critical patent/JP2002504318A/ja
Priority to EP99915493A priority patent/EP1056857A2/de
Publication of WO1999042477A2 publication Critical patent/WO1999042477A2/de
Publication of WO1999042477A8 publication Critical patent/WO1999042477A8/de
Publication of WO1999042477A3 publication Critical patent/WO1999042477A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs

Abstract

Beschrieben wird ein Nukleinsäuremolekül aus einer Zuckertransporterfamilie, wobei die Nukleinsäure für ein Protein mit der biologischen Aktivität eines Transporters für Saccharid-gekoppelte Arzneimittel kodiert. Ferner werden diese Nukleinsäuremoleküle enthaltende Vektoren beschrieben, wobei in einer bevorzugten Ausführungsform diese Vektoren zur Expression des Transporters in Prokaryonten oder Eukaryonten sowie zur Gentherapie geeignet sind. Ausserdem werden davon codierte Proteine und Antikörper beansprucht, welche diese Proteine spezifisch erkennen. Mit diesen erfindungsgemässen Gegenständen können Zellen, vorzugsweise Tumorzellen, auf das Vorhandensein eines solchen Transporters untersucht werden. Bei Fehlen des beschriebenen Transporters in Zellen kann dieser auf gentherapeutischem Weg eingebracht werden. Tumorzellen können auf diesem Weg wirkungsvoller als bisher möglich einer Chemotherapie zugänglich gemacht werden.
PCT/DE1999/000535 1998-02-18 1999-02-18 Transporterprotein für saccharid-gekoppelte arzneimittel WO1999042477A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000532429A JP2002504318A (ja) 1998-02-18 1999-02-18 糖結合薬物用輸送体タンパク質
EP99915493A EP1056857A2 (de) 1998-02-18 1999-02-18 Transporterprotein für saccharid-gekoppelte arzneimittel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19806803.4 1998-02-18
DE19806803A DE19806803A1 (de) 1998-02-18 1998-02-18 Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen

Publications (3)

Publication Number Publication Date
WO1999042477A2 WO1999042477A2 (de) 1999-08-26
WO1999042477A8 WO1999042477A8 (de) 1999-11-04
WO1999042477A3 true WO1999042477A3 (de) 2000-03-30

Family

ID=7858192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/000535 WO1999042477A2 (de) 1998-02-18 1999-02-18 Transporterprotein für saccharid-gekoppelte arzneimittel

Country Status (4)

Country Link
EP (1) EP1056857A2 (de)
JP (1) JP2002504318A (de)
DE (1) DE19806803A1 (de)
WO (1) WO1999042477A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002083857A2 (en) * 2001-04-10 2002-10-24 Millennium Pharmaceuticals, Inc. 68723, sodium/glucose cotransporter family members and uses therefor
WO2004065576A2 (en) * 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
US20130281386A1 (en) * 2012-04-19 2013-10-24 Eleison Pharmaceuticals LLC Glufosfamide Combination Therapies for Cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002125862, Database accession no. U41897 *
DATABASE TREMBL PROTEIN SEQUE 1 January 1900 (1900-01-01), XP002125863, Database accession no. O15279 *
MACKENZIE, B. ET AL.: "SAAT1 Is a Low Affinity Na+/Glucose Cotransporter and not an Amino Acid Transporter", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 36, 9 September 1994 (1994-09-09), pages 22488 - 22491, XP002125491 *
POHL, J. ET AL.: "D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 35, no. 5, 1995, pages 364 - 370, XP000673179 *
POPPE, R. ET AL.: "Expression of the Na+-D-Glucose Cotransporter SGLT1 in Neurons", JOURNAL OF NEUROCHEMISTRY, vol. 69, no. 1, July 1997 (1997-07-01), pages 84 - 94, XP002125724 *
VEYHL, M. ET AL.: "Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 6, 17 March 1998 (1998-03-17), pages 2914 - 2929, XP002125492 *

Also Published As

Publication number Publication date
EP1056857A2 (de) 2000-12-06
WO1999042477A2 (de) 1999-08-26
WO1999042477A8 (de) 1999-11-04
JP2002504318A (ja) 2002-02-12
DE19806803A1 (de) 1999-11-25

Similar Documents

Publication Publication Date Title
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
WO2000014228A8 (fr) Transporteur d'acides amines neutres et gene correspondant
HK1082761B (zh) 具有複製的條件起源的循壞dna分子，其製備方法及其在基因治療中的應用
WO1988007576A3 (fr) Proteines vasculaires anticoagulantes, leurs adn de codage, production et utilisation
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
NO984415D0 (no) Peptider med antiproliferative egenskaper
EP1009752A4 (de) Neue moleküle aus der familieder tango-77-ähnlichen proteine und ihre verewendungen.
Liu Chemical synthesis of proteins that cannot be obtained recombinantly
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO2002078526A3 (en) Cancer-testis antigens
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
CA2281955A1 (en) Ikb kinase, subunits thereof, and methods of using same
WO1998011234A3 (en) Human protein kinases
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO1999042477A3 (de) Transporterprotein für saccharid-gekoppelte arzneimittel
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2000043510A3 (en) Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
AU5569600A (en) Novel protein and dna thereof
WO2001032693A3 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
Cazacu‐Davidescu et al. Influence of non‐enzymatic glycosylation (glycation) of pea (Pisum sativum) albumins on their enzymatic hydrolysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999915493

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915493

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999915493

Country of ref document: EP